Pacira BioSciences, Inc. (PCRX)

NASDAQ: PCRX · IEX Real-Time Price · USD
19.37
-0.85 (-4.20%)
At close: Jul 19, 2024, 4:00 PM
20.18
+0.81 (4.18%)
After-hours: Jul 19, 2024, 6:36 PM EDT
-4.20%
Market Cap 901.60M
Revenue (ttm) 681.75M
Net Income (ttm) 70.47M
Shares Out 46.55M
EPS (ttm) 1.45
PE Ratio 13.36
Forward PE 6.37
Dividend n/a
Ex-Dividend Date n/a
Volume 1,043,147
Open 20.27
Previous Close 20.22
Day's Range 19.34 - 20.58
52-Week Range 19.34 - 40.16
Beta 0.88
Analysts Strong Buy
Price Target 46.10 (+138.0%)
Earnings Date Jul 31, 2024

About PCRX

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and sup... [Read more]

Sector Healthcare
IPO Date Feb 3, 2011
Employees 712
Stock Exchange NASDAQ
Ticker Symbol PCRX
Full Company Profile

Financial Performance

In 2023, PCRX's revenue was $674.98 million, an increase of 1.22% compared to the previous year's $666.82 million. Earnings were $41.96 million, an increase of 163.72%.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for PCRX stock is "Strong Buy." The 12-month stock price forecast is $46.1, which is an increase of 138.00% from the latest price.

Price Target
$46.1
(138.00% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025

-- Proposed Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment System Rule extends separate payment from ambulatory surgical centers to include the hospital outpatient envi...

10 days ago - GlobeNewsWire

Top 5 Health Care Stocks That May Explode In July

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: CSTLNRCOMISAVA
12 days ago - Benzinga

This Charter Communications Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...

Other symbols: CHTRAZEKSPR
17 days ago - Benzinga

Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference

TAMPA, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2024 Jefferies Global Healthcare C...

7 weeks ago - GlobeNewsWire

Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029

TAMPA, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced the pricing of $250.0 million aggregate principal amount of convertible senior notes due 2029 (the...

2 months ago - GlobeNewsWire

Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes

TAMPA, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that it intends to offer, subject to market and other conditions, $250.0 million aggregate princip...

2 months ago - GlobeNewsWire

Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program

-- Conference call today at 4:30 p.m. ET -- TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management a...

2 months ago - GlobeNewsWire

Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference

TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2024 RBC Capital Markets Global He...

2 months ago - GlobeNewsWire

Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024

TAMPA, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results after the close of the U.S. markets on Tu...

2 months ago - GlobeNewsWire

Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

TAMPA, Fla., April 02, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 23rd Annual Needham Virtual Heal...

3 months ago - GlobeNewsWire

Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee

-- PCRX-201 is the first gene therapy product candidate to receive RMAT designation for osteoarthritis -- -- Designation supported by encouraging preliminary data from 72-patient Phase 1 study --

4 months ago - GlobeNewsWire

Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference

TAMPA, Fla., March 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays 26th Annual Global Heal...

4 months ago - GlobeNewsWire

Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results

— Record revenues of $675 million in 2023 — — Full-year GAAP net income of $42 million and adjusted EBITDA of $214 million — — EXPAREL surpasses the 14 million patient mark — — Conference call today a...

5 months ago - GlobeNewsWire

Pacira to Report 2023 Financial Results on Thursday February 29, 2024

TAMPA, Fla., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2023 financial results before t...

5 months ago - GlobeNewsWire

Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy

– Findings demonstrate significant reduction in pain and opioid consumption through 96 hours versus active comparator –

5 months ago - GlobeNewsWire

Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.

TAMPA, Fla., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc., (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, has been...

5 months ago - GlobeNewsWire

G.O.A.T. Bowl I Registration Open to 4 Additional Pickleball Teams

High Demand for Participation in Pickleball's Big Game on Feb. 9 in Las Vegas Leads to Tournament's Expansion to 24 Teams and Signing of New Sponsors LAS VEGAS , Feb. 1, 2024 /PRNewswire/ -- Paradise ...

6 months ago - PRNewsWire

Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues

TAMPA, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today rep...

7 months ago - GlobeNewsWire

Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

TAMPA, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 42nd Annual J.P. Morgan Healthcare Conference at 8:15 AM PT (11:15 AM...

7 months ago - GlobeNewsWire

20 favorite small-cap stocks for 2024 among Wall Street analysts

The 2023 stock-market rally has been led by the “Magnificent Seven” companies, which have driven an accelerating upward trend for the large-cap benchmark S&P 500. Shares of smaller and medium-sized co...

7 months ago - Market Watch

Pacira Appoints Frank D. Lee as Chief Executive Officer

-- Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization -- -- Paul J. Hastings Named Chair of the Board --

7 months ago - GlobeNewsWire

Pacira Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications

— EXPAREL is the only FDA-approved single-dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies —

9 months ago - GlobeNewsWire

Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in November

TAMPA, Fla., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferen...

9 months ago - GlobeNewsWire

Pacira BioSciences Reports Third Quarter 2023 Financial Results

-- New ASA initiatives to advance education and innovation for the anesthesia community -- -- PDUFA action date for EXPAREL as a lower extremity nerve block on track for November 13, 2023 --

9 months ago - GlobeNewsWire

Pacira to Report Third Quarter 2023 Financial Results on Thursday November 2, 2023

TAMPA, Fla., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Thu...

9 months ago - GlobeNewsWire